Bioton SA
WSE:BIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioton SA
Total Liabilities & Equity
Bioton SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioton SA
WSE:BIO
|
Total Liabilities & Equity
zł764.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
M
|
Mabion SA
WSE:MAB
|
Total Liabilities & Equity
zł120.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Total Liabilities & Equity
zł15.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
G
|
Genomed SA
WSE:GEN
|
Total Liabilities & Equity
zł12.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
U
|
Urteste SA
WSE:URT
|
Total Liabilities & Equity
zł29.6m
|
CAGR 3-Years
41%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Total Liabilities & Equity
zł304.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
30%
|
CAGR 10-Years
7%
|
|
Bioton SA
Glance View
BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
See Also
What is Bioton SA's Total Liabilities & Equity?
Total Liabilities & Equity
764.6m
PLN
Based on the financial report for Dec 31, 2025, Bioton SA's Total Liabilities & Equity amounts to 764.6m PLN.
What is Bioton SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-9%
Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Bioton SA have been -2% over the past three years , -2% over the past five years , and -9% over the past ten years .
